None

Liver injury prompts agomelatine label update

Doctors have been warned of "several serious cases of hepatotoxicity" associated with Servier's antidepressant Valdoxan/Thymanax (agomelatine), including six reports of hepatic failure, since the dru...

Nectid commences clinical development of agomelatine in US

Nectid, a drug discovery company, has initiated clinical development of agomelatine for autism and pain indications in the US.

Electrophysiological Effects of Repeated Administration of Agomelatine on the Dopamine, Norepinephrine, and Serotonin Systems in the Rat Brain

Human medicines European Public Assessment Report (EPAR): Valdoxan, agomelatine, Revision: 9, Authorised

Human medicines European Public Assessment Report (EPAR): Thymanax, agomelatine, Revision: 7, Authorised

Human medicines European Public Assessment Report (EPAR): Valdoxan, agomelatine, Revision: 8, Authorised

Human medicines European Public Assessment Report (EPAR): Thymanax, agomelatine, Revision: 6, Authorised

Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs

PRINCETON, N.J., Aug. 16, 2012 /PRNewswire/ -- Nectid, Inc. (www.nectid.com), a Princeton based pharmaceutical product development company focused on discovering and developing novel drugs, annou...

QTc Prolongation During Treatment with Agomelatine.

A 58 years old woman with a depression showed a QTc prolongation during treatment with agomelatine which was fully reversible after stopping administration. QTc prolongation during antidepressant trea...

{blacktriangledown}Agomelatine for major depressive episodes.

black triangle downAgomelatine (Valdoxan - Servier) is an antidepressant licensed for treating patients with major depressive episodes. The drug company's website for agomelatine states that the drug...

The effects of agomelatine on sexual function in depressed patients and healthy volunteers.

BACKGROUND: Selective serotonin reuptake inhibitor (SSRI) and serotonin and norepinephrine reuptake inhibitor antidepressants are associated with high rates of treatment-emergent sexual dysfunction (T...

Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.

Agomelatine is the first approved antidepressant that mediates its activity through the melatoninergic pathway rather than the monoaminergic system. This meta-analysis aims to summarize an up-to-date...

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT(2c) antagonist, S32006.

The novel melatonergic agonist/5-HT(2C) antagonist agomelatine displays robust antidepressant properties in humans and is active in pre-clinical models predictive of antidepressant effects. In this st...